Prestige Biologics Co., Ltd.

A334970

KR7334970001

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 30/06/2024 BST			5-day change	1st Jan Change
4,065 ^KRW	+1.88%		-1.93%	-7.61%

2023	Prestige Biologics Co., Ltd. announced that it has received KRW 45.5 billion in funding from Octava Fund Limited	CI
2023	Prestige Biologics Co., Ltd. announced that it expects to receive KRW 45.5 billion in funding from Octava Fund Limited	CI

Prestige Biologics Co., Ltd. has completed an IPO in the amount of KRW 91.14 billion.

March 08, 2021 at 05:00 am

Prestige Biologics Co., Ltd. has completed an IPO in the amount of KRW 91.14 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 7,350,000 PriceRange: KRW 12400 Discount Per Security: KRW 706.8 Transaction Features: Sponsor Backed Offering

Latest news about Prestige Biologics Co., Ltd.

Prestige Biologics Co., Ltd. announced that it has received KRW 45.5 billion in funding from Octava Fund Limited	19/03/23	CI
Prestige Biologics Co., Ltd. announced that it expects to receive KRW 45.5 billion in funding from Octava Fund Limited	13/03/23	CI
Prestige Biologics Co., Ltd. announced that it has received KRW 6.893915 billion in funding from Prestige BioPharma Limited	04/09/22	CI
Prestige Biologics Co., Ltd. announced that it expects to receive KRW 6.893915 billion in funding from Prestige BioPharma Limited	25/08/22	CI
Prestige BioPharma and Dr. Reddy's Announce Partnership to Commercialize Trastuzumab Biosimilar in Select Countries in Latin America and Southeast Asia	09/12/21	CI
Prestige Biologics Co., Ltd.(KOSDAQ:A334970) added to S&P Global BMI Index	20/09/21	CI
Prestige Biologics Co., Ltd. has completed an IPO in the amount of KRW 91.14 billion.	08/03/21	CI
Prestige Biologics Co., Ltd. has filed an IPO.	21/08/20	CI

Chart Prestige Biologics Co., Ltd.

Duration

Period

More charts

Company Profile

Prestige Biologics Co Ltd is a Korean-based company mainly engaged in the business of developing and manufacturing biopharmaceuticals. The Company mainly engages in the contract manufacturing service business that produces and supplies biopharmaceuticals; and contract development service business that provides development services including cell culture process and purification process.

Sector

Pharmaceuticals

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
PRESTIGE BIOLOGICS CO., LTD.	-7.61%	178M
CSL LIMITED	+2.08%	95.18B
SAMSUNG BIOLOGICS CO.,LTD.	-0.13%	37.55B
BIOGEN INC.	-10.71%	33.75B
UCB	+77.76%	28.2B
BIOMARIN PHARMACEUTICAL INC.	-15.21%	15.63B
INCYTE CORPORATION	-3.36%	13.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.76%	11.5B
ALTEOGEN INC.	+181.73%	10.81B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-53.92%	9.23B